[Comparison of IPSS-R and IPSS-M in newly diagnosed myelodysplastic neoplasms: a single-center study].

• DOI: 10.11406/rinketsu.66.7
• Publication Date: 2025-01-01
• Authors: Shunsuke Otsuki; Seiichiro Katagiri; Yuya Arai; Shinichi Wakamatsu; Masatoshi Moriyama; Akiko Yamada; Tamiko Suguro; Michiyo Asano; Seiichiro Yoshizawa; Daigo Akahane; Yuko Tanaka; Nahoko Furuya; Hiroaki Fujimoto; Seiichi Okabe; Moritaka Gotoh; Yoshikazu Ito; Hironori Harada; Yuka Harada; Akihiko Gotoh
• Keywords: Single Center; Center (category theory)

We compared the International Prognostic Scoring System-Revised (IPSS-R) to System-Molecular (IPSS-M) in 30 patients with myelodysplastic neoplasms (MDS) newly diagnosed at our institution from January 2021 February 2023. Molecular analysis was performed by myeloid panel. The median age 66 years (range: 35-80), and classifications were MDS-LB (n=18), MDS IB-1 (n=1), IB-2 (n=2), MDS-SF3B1 MDS-biTP53 MN-pCT (n=6). Each patient had 0 8 (median 1) mutations. most frequently detected mutation TET2 mutation, others in>5 U2AF1, TP53, RUNX1 IPSS-R classification indicated that 2, 14, 5, 3, 6 very low, intermediate (Int), high, high risk, respectively, whereas IPSS-M 9, 7, 4, 5 cases moderate-low (ML), moderate-high (MH), respectively. Considering ML MH as equivalent Int, 13 (43%) a different risk level IPSS-R. One rated low-risk IPSS-R, but reclassified IPSS-M. It is important be mindful of this potential for significant discrepancies between assessments using some when making treatment decisions.